Bi­par­ti­san let­ter ques­tions FDA's 'nar­row' in­ter­pre­ta­tion for pri­or­i­ty re­view vouch­ers

Sen. Tim Scott (R-SC) and Rep. Dan­ny Davis (D-IL) are ques­tion­ing the FDA’s “nar­row” in­ter­pre­ta­tion of “ac­tive in­gre­di­ent” when it comes to award­ing the po­ten­tial­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER